- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | D.Boral Capital: Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference | 181 | Newsfile | Cambridge, Massachusetts--(Newsfile Corp. - May 8, 2025) - Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May... ► Artikel lesen | |
| Mi | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 29.04. | Ernexa reports promising cancer cell therapy study results | 2 | Investing.com | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.04. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 | 1 | GlobeNewswire (USA) | ||
| 03.04. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Closes New Funding Round | 142 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
| 03.04. | Eterna Therapeutics Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 25.03. | Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease | 106 | GlobeNewswire (Europe) | Ernexa Therapeutics embarks on new strategic direction, shifting the company's focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company's... ► Artikel lesen | |
| 24.03. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | Eterna Therapeutics Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.03. | Eterna Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.02. | Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline | 6 | GlobeNewswire (USA) | ||
| 13.02. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.01. | Eterna Therapeutics expands scientific board with oncology experts | - | Investing.com | ||
| 28.01. | Eterna Therapeutics erweitert wissenschaftlichen Beirat mit Onkologie-Experten | 8 | Investing.com Deutsch | ||
| 28.01. | Eterna Therapeutics Announces Expansion of Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| 14.01. | Eterna Therapeutics reports breakthrough in ovarian cancer treatment | 4 | Investing.com | ||
| 14.01. | Eterna Therapeutics meldet Durchbruch bei der Behandlung von Eierstockkrebs | 13 | Investing.com Deutsch | ||
| 14.01. | Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer | 153 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced positive results from... ► Artikel lesen | |
| 10.01. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.01. | Eterna Therapeutics Appoints Dr. Elena Ratner To Board Of Directors | 1 | RTTNews |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,089 | +5,58 % | XFRA PTN: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPALATIN TECHS DL-... ► Artikel lesen | |
| BIOXXMED | 0,410 | -8,89 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,930 | -100,00 % | VivoSim Labs, INC. - 8-K, Current Report | ||
| OCUGEN | 0,588 | -1,01 % | Ocugen Provides Business Update with First Quarter 2025 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 0,640 | 0,00 % | Bio-Gate startet Produkt-Launch für Tierpflege in den USA | Bio-Gate hat die Präsenz im nordamerikanischen Veterinärmarkt ausgebaut. Gemeinsam mit einem internationalen Anbieter bringt Bio-Gate neue Tierpflegeprodukte zur Haut-, Ohr- und Wundbehandlung in die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,602 | -1,31 % | Evotecs KI-Goldgrube, Defence Therapeutics Milliarden-Märkte, Novo Nordisks Diät-Revolution: So verdienen Anleger mit | Die Gesundheitsbranche befindet sich im Umbruch. Algorithmen beschleunigen die Arzneimittelforschung um Jahre, Milliarden fließen in personalisierte Therapien, und Börsen feiern Biotech-Aktien. Doch... ► Artikel lesen | |
| VAXART | 0,348 | -6,61 % | Vaxart, Inc.: Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress | Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,062 | +0,32 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,226 | +2,73 % | Cellectar Biosciences, Inc.: Cellectar Announces Plan to Explore Strategic Alternatives | FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization... ► Artikel lesen | |
| AFFIMED | 0,530 | -100,00 % | Affimed N.V.: Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists | ||
| IMMUNIC | 0,919 | +2,80 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Industry Conferences in May | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Industry Conferences in May
02.05.2025 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,145 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 0,216 | -1,28 % | CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer | VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments.
"We... ► Artikel lesen |
ERNEXA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,200 Euro und damit -0,15 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.